Table 2.
The details of the included studies.
| Serial number | Studies | Year | N (T/C) | Treatment group | Control group | Course (week) | Outcomes |
|---|---|---|---|---|---|---|---|
| 1 | Chen and Shan (25) | 2014 | 100 (50/50) | WXKL + Metalol tartrate | Metalol tartrate | 4 | a.b.c.d |
| 2 | Zhao (26) | 2018 | 80 (40/40) | WXKL + Betaloc | Betaloc | 4 | a.b.c |
| 3 | Xu et al. (27) | 2009 | 64 (32/32) | WXKL + Betaloc | Betaloc | 4 | a.b.c.d |
| 4 | Wang (28) | 2017 | 88 (45/43) | WXKL + Betaloc | Betaloc | 16 | a.b.d |
| 5 | Xu (29) | 2014 | 87 (43/44) | WXKL + Betaloc | Betaloc | 4 | a.b.c |
| 6 | Luo et al. (30) | 2013 | 64 (32/32) | WXKL + Metalol tartrate | Metalol tartrate | 4 | a.b.c |
| 7 | Zhang et al. (31) | 2009 | 103 (53/50) | WXKL + Betaloc | Betaloc | 4 | a.b.c |
| 8 | Wang et al. (32) | 2014 | 108 (54/54) | WXKL + Betaloc | Betaloc | 4 | a.b.c.d |
| 9 | Wu (33) | 2014 | 64 (32/32) | WXKL + Metoprolol | Metoprolol | 4 | a.b.c |
| 10 | Zhang (34) | 2015 | 112 (54/58) | WXKL + Metoprolol | Metoprolol | 4 | a.b.c |
| 11 | Dai and Zhengdong (35) | 2017 | 84 s(42/42) | WXKL + Metalol tartrate | Metalol tartrate | 4 | a.b.c |
Outcomes: a. Clinical efficacy; b. 24 h electrocardiogram; c. Subjective adverse reactions (dizziness, nausea, etc.). d. Liver and kidney damage.